In the present study, we aimed to evaluate temporal changes in heart-type fatty acid-binding protein (h-FABP) and myocardial performance index (Tei index) following administration of 5-fluorouracil (5-FU), a chemotherapeutic agent associated with myocardial ischemia induced by coronary vasospasm. Thirty-two patients with cancer receiving their first 5-FU-based chemotherapy were included in the study. Prior to chemotherapy and 24 hours after the initiation of chemotherapy, all patients underwent a comprehensive echocardiographic examination. Blood samples were taken for h-FABP and troponin I (TnI) measurements at different time points during the first 24 hours of 5-FU administration. Postinfusion echocardiography revealed worsening in Tei index (0.37 ± 0.08 vs 0.43 ± 0.07, P < .001). Clinically overt cardiotoxicity was evident in 4 (12.5%) of our patient population. Heart-type fatty acid binding protein and TnI levels were within normal ranges at all time points. Our results suggest that ischemia coronary vasospasm due to 5-FU cardiotoxicity should be reviewed. Furthermore, Tei index might be a sensitive indicator of occult 5-FU cardiotoxicity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/0003319716637516 | DOI Listing |
J Clin Med
November 2024
Department for Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, 48149 Münster, Germany.
Heart failure (HF) remains a major therapeutic and diagnostic challenge nowadays. Albeit, acute decompensated HF is associated with several clinical signs such as dyspnea or edema, it remains a challenge to use easy accessible and suitable tools, such as biomarkers, to distinguish between patients at risk for an acute decompensation of their heart failure and compensated, stable HF patients. Existing biomarkers, such as natriuretic peptides or troponin, are not specific and can be elevated due to several other disease conditions, such as myocardial infarction, atrial fibrillation, or valve diseases.
View Article and Find Full Text PDFJ Immunoassay Immunochem
November 2024
Department of Biochemistry, Faculty of Science, Helwan University, Cairo, Egypt.
Aim: In 2019, cardiovascular diseases accounted for 32% of global deaths. So, early detection of cardiac disorders is crucial. The study aimed to examine the suitability of Pro-neurotensin and Heart-type fatty acid binding protein as dependable biomarkers for cardiac patients with Heart failure as a primary diagnosis.
View Article and Find Full Text PDFJ Assoc Physicians India
November 2024
Consultant and Head, Department of Cardiology, Safdarjung Hospital, Delhi, India.
Am J Transl Res
October 2024
Emergency Department, West China Hospital of Sichuan University Chengdu 610000, Sichuan, China.
Objective: To investigate the correlation between serum levels of Heart-type fatty acid binding protein (H-FABP), Soluble Triggering Receptor Expressed on Myeloid Cells 1 (sTREM-1), and High mobility group box 1 protein (HMGB1) with disease severity, and their prognostic value in sepsis.
Methods: A retrospective analysis was conducted using the clinical data from 86 sepsis patients admitted to West China Hospital of Sichuan University between June 2021 and December 2023, and these cases constituted the observation group. In addition, clinical data from 80 healthy individuals who underwent medical examinations at our hospital during the same period served as the control group.
Am J Transl Res
October 2024
Department of Anesthesiology and Perioperative Medicine, Xingyuan Hospital of Yulin/4th Hospital of Yulin No. 33 Xirenmin Road, Yuyang District, Yulin 719000, Shaanxi, China.
Objective: This retrospective study aimed to evaluate the impact of intraoperative dexmedetomidine on myocardial injury markers (heart-type fatty acid binding protein [H-FABP], creatine kinase-mb [CK-MB], and cardiac troponin I [cTnI]) and postoperative delirium in patients undergoing heart valve replacement.
Methods: Clinical data from 160 cardiac patients who underwent heart valve replacement with cardiopulmonary bypass (CPB) between January 2019 and January 2024 were analyzed. Patients were divided into an observation group (n = 82) receiving dexmedetomidine and a control group (n = 78) without dexmedetomidine.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!